June 2023 Global Innovative Drug Report 

Our newly published June 2023 Global Innovative Drug Report offers a comprehensive overview of the latest pharma advancements. It covers a detailed analysis of each selected drug, examining its active patents, mechanisms of action, associated clinical trials, competitive landscape, and more.

This report explores:

1. The first approved drugs in June 

2. New drug analysis 

3. Global drugs under expedited review pathway in June 

4. Analysis of selected ERP drugs 

Global Innovative Drug Report Summary

1.) First Approved Drugs in June 

June 2023 was a busy month for drug approvals, with 14 new drugs getting the green light. These new approvals include seven small molecule drugs (SMD), one monoclonal antibody (mAb), one enzyme, 1 CAR-T, one FcRN, one cell therapy, one micro-dystrophin, and one traditional Chinese medicine.

2.) Comprehensive analysis of newly introduced medications 

This report also highlights five recently approved and provides an in-depth analysis of each. Here’s an example of the details can expect to uncover, using the example of Vorolanib:

3.) Global Drugs under Expedited Review Pathway in June 

In June 2023, 58 drugs were under expedited review pathways. The designations include:

• 32 orphan drugs
• 12 fast track
• 9 priority review
• 4 breakthrough therapy
• 2 accelerated approval
• 1 qualified infectious disease product
• 1 PRIME

4.) Analysis of Selected ERP Drugs 

Our experts also selected six ERP drugs to analyze. Here’s an example of the information contained for each, using PRGN-12:

Gain Access to the Comprehensive Report for FREE – Download Now! If you aren’t registered for Synapse (registration is required to download the report), click here to register for free.

PatSnap Synapse Database: An Overview and Key Features

Discover the innovative PatSnap Synapse database – an AI-powered platform that provides intuitive interfaces, curated content, and access to massive information sources. With integrated access to company data, diseases, targets, clinical studies, biological and chemical entities, our platform offers a powerful search and association experience. Sign up for free today and experience the benefits for yourself!

R&D Decision Makers

Our mission is to empower R&D decision makers with swift access to accurate and connected data, facilitating their understanding of emerging technology trends, competitive landscapes, and partnership opportunities. By providing comprehensive insights, our platform helps decision makers to navigate and steer the direction of innovation with confidence.

Business Development Professionals 

We offer a comprehensive database that covers the drug pipeline and investment history for over 320,000 life science organizations. This invaluable resource allows you to make informed decisions regarding potential partnerships or acquisition targets with confidence. Gain access to our extensive database and unlock the insights you need to drive your business forward.

Pharmaceutical Analyst 

Our platform is designed to accelerate the research process for pharmaceutical analysts by leveraging a wealth of connected data, including drug approvals, clinical trials, patents, non-patent literature, and news. With Synapse, users gain a comprehensive 360-degree view of the competitive and technological landscape, empowering them to make informed decisions quickly and efficiently. Discover the power of Synapse and revolutionize your research today.

Copyright Statement: This report is the sole property of Patsnap and is protected under copyright laws. Any reproduction, excerpting, or other use of this report without explicit authorization from Patsnap is strictly prohibited. Authorized products must be used within the scope of authorization and must include a clear indication of the source. Patsnap reserves the right to investigate any violations of this statement and pursue legal action as necessary. For inquiries regarding authorization, please contact [email protected].